对治疗有应答的患者中积极传统疗法与三种生物制剂治疗的直接比较及两种降阶梯策略比较:多中心、随机、开放标签、评估者盲法4期研究方案
NORD-STAR研究为多中心、随机、开放标签、评估者盲法4期研究,纳入800例早期类风湿关节炎(症状持续时间小于24个月)患者,1:1:1:1随机分至四组:积极csDMARD治疗(甲氨蝶呤+柳氮磺吡啶+羟氯喹+关节腔内糖皮质激素或甲氨蝶呤+口服泼尼松龙)、甲氨蝶呤+培塞利珠单抗聚乙二醇、甲氨蝶呤+阿巴西普或甲氨蝶呤+托珠单抗,主要终点为第24周达到CDAI缓解的患者比例;持续缓解者进入第二部分重新随机接受立即或延迟(24周后)降阶梯策略。
要点
- NORD-STAR首次在早期RA中头对头比较积极csDMARD与三种不同作用机制bDMARD治疗。
- 研究还将比较对一线治疗有应答者的两种降阶梯策略:立即减量 vs 延迟(24周后)减量。
- 主要终点为第24周CDAI缓解比例;第二部分主要终点为启动降阶梯后24周缓解(CDAI≤2.8)比例。
核心结论
- NORD-STAR是首个研究者发起的、在早期RA中头对头比较csDMARD与三种不同bDMARD治疗以及两种降阶梯策略的随机试验。
- 该试验有潜力确定早期RA应采用何种治疗策略,以实现患者和社会的最佳结局。
研究设计与样本
- 务实性、80-160周、多中心、随机、开放标签、评估者盲法4期研究。
- 纳入800例早期RA患者(症状持续时间小于24个月),按1:1:1:1随机分至四个治疗组。
- 第一组为积极csDMARD治疗:甲氨蝶呤+柳氮磺吡啶+羟氯喹+关节腔内糖皮质激素(1A组)或甲氨蝶呤+口服泼尼松龙(1B组)。
- 第二至四组分别为甲氨蝶呤+培塞利珠单抗聚乙二醇、甲氨蝶呤+阿巴西普、甲氨蝶呤+托珠单抗。
- 持续缓解超过连续24周的患者最早在第48周后进入第二部分,重新随机接受立即或延迟(24周后)减量后停药;未达到持续缓解者第80周退出研究;所有患者维持稳定剂量甲氨蝶呤。
主要发现
- 主要临床终点为第24周达到临床疾病活动指数(CDAI)缓解的患者比例。
- 第二部分主要临床终点为启动降阶梯治疗24周后处于缓解(CDAI≤2.8)的患者比例。
- 整个试验期间定期进行影像学评估,血液和尿液样本储存于生物样本库供后续生物标志物分析。
关键数值与推荐
- 早期RA定义为症状持续时间小于24个月。
- 第一部分主要终点:第24周CDAI缓解比例。
- 第二部分主要终点:启动降阶梯后24周CDAI≤2.8的缓解比例。
- 持续缓解定义为连续24周处于稳定缓解。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: New targeted therapies and improved treatment strategies have dramatically improved the outcomes of patients with rheumatoid arthritis (RA). However, it is unknown whether different early aggressive interventions can induce stable remission or a low-active disease state that can be maintained with conventional synthetic disease-modifying antirheumatic drug (csDMARD) therapy, and whether they differ in efficacy and safety. The Nordic Rheumatic Diseases Strategy Trials And Registries (NORD-STAR) study will assess and compare (1) the proportion of patients who achieve remission in a head-to-head comparison between csDMARD plus glucocorticoid therapy and three different biological DMARD (bDMARD) therapies with different modes of action and (2) two de-escalation strategies in patients who respond to first-line therapy. METHODS/DESIGN: In a pragmatic, 80-160-week, multicenter, randomized, open-label, assessor-blinded, phase 4 study, 800 patients with early RA (symptom duration less than 24 months) are randomized 1:1:1:1 to one of four different treatment arms: (1) aggressive csDMARD therapy with methotrexate + sulphasalazine + hydroxychloroquine + i.a. glucocorticoids (arm 1A) or methotrexate + prednisolone p.o. (arm 1B), (2) methotrexate + certolizumab-pegol, (3) methotrexate + abatacept, or (4) methotrexate + tocilizumab. The primary clinical endpoint is the proportion of patients reaching Clinical Disease Activity Index (CDAI) remission at week 24. Patients in stable remission over 24 consecutive weeks enter part 2 of the study earliest after 48 weeks. Patients not achieving sustained CDAI remission over 24 consecutive weeks, exit the study after 80 weeks. In part 2, patients are re-randomized to two different de-escalation strategies, either immediate or delayed (after 24 weeks) tapering, followed by cessation of study medication. All patients remain on stable doses of methotrexate. The primary clinical endpoint in part 2 is the proportion of patients in remission (CDAI ≤2.8) 24 weeks after initiating treatment de-escalation. Radiographic assessment will be performed regularly throughout the trial, and blood and urine samples will be stored in a biobank for later biomarker analyses. DISCUSSION: NORD-STAR is the first investigator-initiated, randomized, early RA trial to compare (1) csDMARD and three different bDMARD therapies head to head and (2) two different de-escalation strategies. The trial has the potential to identify which treatment strategy to apply in early RA to achieve the best possible outcomes for both patients and society. TRIAL REGISTRATION: NCT01491815 and NCT02466581 . Registered on 8 December 2011 and May 2015, respectively. EudraCT: 2011-004720-35.
引用
- Glinatsi D, Heiberg MS, Rudin A, et al. Head-to-head comparison of aggressive conventional therapy and three biological treatments and comparison of two de-escalation strategies in patients who respond to treatment: study protocol for a multicenter, randomized, open-label, blinded-assessor, phase 4 study. Trials. 2017. PMID: 28376912. doi:10.1186/s13063-017-1891-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。